Diabetes Flashcards

1
Q

Type 1 diabetes

A

Pancreas stops being able to produce adequate insulin
Without insulin, the cells cannot absorb glucose from the blood and use it as fuel & therefore think no glucose is available, whilst glucose level keeps rising = hyperglycaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Type 1 diabetes classic triad symptoms

A

Polyuria
Polydipsia
Weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Ketogenesis

A

Occurs when there is insufficient glucose supply and glycogen stores are exhausted
Liver takes fatty acids and converts them to ketones (water-soluble fatty acids)
Can cross the BBB and be used by the brain
Level can be measured in the urine with a dipstick and in the blood using a ketone meter, people in ketosis = acetone smell to their breath
Kidneys buffer ketone acids in healthy people, so blood does not become acidotic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Diabetic ketoacidosis pathophysiology

A

1) Ketoacidosis – without insulin, cells cannot recognise glucose, so liver starts producing ketones to use as fuel; over time there are high glucose and ketones levels; initially kidneys produce bicarbonate to counteract the ketone acids in the blood & maintain normal pH; over time, ketone acids use up the bicarbonate & blood becomes acidic
2) Dehydration – hyperglycaemia overwhelms the kidneys and glucose leaks into the urine, glucose in the urine draws water out by osmotic diuresis -> polyuria and severe dehydration -> polydipsia
3) Potassium imbalance – when treatment with insulin starts, patients can develop severe hypokalaemia very quickly, leading to fatal arrhythmias

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Diabetic ketoacidosis symptoms

A

Polyuria
Polydipsia
N&V
Acetone smell to their breath
Dehydration
Weight loss
Hypotension
Altered consciousness

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

DKA diagnosis

A

Hyperglycaemia (BM>11)
Ketosis (blood ketones > 3 mmol/L)
Acidosis (pH < 7.3)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

DKA treatment

A

Priority is fluid resuscitation to correct dehydration, electrolyte disturbance and acidosis
Followed by insulin infusion to get the cells to start taking up and using glucose and stop producing ketones
F – fluids
I – insulin (fixed rate insulin infusion)
G – glucose (closely monitor BM and add a glucose infusion when it is less than 14)
P – potassium (add K+ to IV fluids)
I – infection (treat underlying triggers such as infection)
C – chart fluid balance
K – ketones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

DKA treatment complications

A

Hypoglycaemia
Hypokalaemia
Cerebral oedema, particularly in children
Pulmonary oedema (secondary to fluid overload/acute respiratory distress syndrome)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Type 1 diabetes long-term management

A

Subcutaneous insulin
Monitoring dietary carbohydrate intake
Monitoring blood sugar levels upon waking, at each meal & before bed
Monitoring for and managing complications, both short and long term

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Insulin pumps

A

Small devices that continuously infuse insulin at different rates to control blood sugar levels
Pump pushes insulin through a small plastic tube (cannula) inserted under the skin
Cannula is replaced every 2-3 days & insertion sites are rotated to prevent lipodystrophy and absorption issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Insulin pumps pros and cons

A

P – better blood sugar control, more flexibility with eating & less injections
C – difficulties learning to use the pump, having it attached at all times, blockages in the infusion set, small risk of infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Tethered vs patch pumps

A

Tethered – devices with replaceable infusion sets and insulin, usually attached to the patient’s belt/around the waist with a tube connecting the pump to the insertion site, controls are on the pump itself
Patch – sit directly on the skin without any visible tubes, entire patch pump is disposed of when insulin runs out, a separate remote usually controls patch pumps

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Type 1 diabetes transplant

A

Pancreas transplant – implanting a donor pancreas to produce insulin
- Original pancreas is left in place to continue producing digestive enzymes
- Life-long immunosuppression is required to prevent rejection so reserved for patients with severe hypoglycaemic episodes & those having kidney transplants
Islet transplantation – inserting donor islet cells into the patient’s liver -> produce insulin
- Patients often still need insulin therapy after islet transplantation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Type 1 diabetes monitoring

A

HbA1c
Capillary blood glucose
Flash glucose monitors – use a sensor on the skin that measures the glucose level of the interstitial fluid in the subcutaneous tissue, 5-minute lag behind blood glucose, need replacing every 2 weeks, 5-minute delay means it is necessary to do CBG testing if hypoglycaemia is suspected
Continuous glucose monitors – similar to flash but send readings over Bluetooth so patient is not required to scan the sensor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

T1DM closed-loop system

A

Artificial pancreas
Combination of a continuous glucose monitor and an insulin pump
Devices communicate to automatically adjust the insulin based on the glucose readings
Patients still need to input carb intake & adjust the system to account for strenuous exercise

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

T1DM short-term complications

A

Hypoglycaemia – caused by too much insulin, not consuming enough carbs or not processing carbs correctly (malabsorption, diarrhoea or vomiting)
- Symptoms: hunger, tremor, sweating, irritability, dizziness and pallor; severe = reduced consciousness, coma and death unless treated
Hyperglycaemia – may indicate that the insulin dose needs to be increased, short episodes of hyperglycaemia do not necessarily require treatment (insulin injections can take several hours to take effect & repeated doses = hypoglycaemia), essential to exclude diabetic ketoacidosis

17
Q

T1DM long-term complications

A

Chronic high glucose causes damage to the endothelial cells of blood vessels
Leads to leaky, malfunctioning vessels that are unable to regenerate
Immune system dysfunction and create an optimal environment for infectious organisms to thrive
Macrovascular – coronary artery disease, peripheral ischaemia (diabetic foot ulcers), stroke, hypertension
Microvascular – peripheral neuropathy, retinopathy, kidney disease (glomerulosclerosis)
Infection – UTI, pneumonia, skin and soft tissue infections, fungal infections (oral and vaginal candidiasis)

18
Q

T2DM

A

Combination of insulin resistance and reduced insulin production cause persistently high blood sugar levels
More and more insulin is required to stimulate the cells to take up and use glucose -> pancreas becomes fatigues and damaged by producing so much insulin & insulin output is reduced

19
Q

T2DM risk factors

A

Non-modifiable – older age, ethnicity (black, south Asian), family history
Modifiable – obesity, sedentary lifestyle, high carbohydrate

20
Q

T2DM symptoms and signs

A

Tiredness
Polyuria and polydipsia
Unintentional weight loss
Opportunistic infections
Slow wound healing
Glucose in urine
Acanthosis nigricans – thickening and darkening of the skin often at the neck, axilla and groin, often associated with insulin resistance

21
Q

Pre-diabetes

A

Indication that the patient is heading towards diabetes
Do not fit the full diagnostic criteria but should be educated about the risk of diabetes and lifestyle changes
HbA1c of 42-47 indicates pre-diabetes

22
Q

T2DM diagnosis

A

HbA1c > 48 mmol/mol or above indicated type 2 diabetes
Sample typically repeated after 1 month to confirm the diagnosis

23
Q

T2DM management

A

Structured education program
Low-glycaemic-index, high-fibre diet
Exercise
Weight loss if overweight
Antidiabetic drugs
Monitoring and managing complications

24
Q

T2DM treatment targets

A

48mmol/mol for new T2DM
53mmol/mol for patients requiring more than one antidiabetic medication

25
Q

T2DM medical management

A

First-line is metformin
Once settled on metformin, add an SGLT-2 inhibitor if patient has existing CVD, HF or QRISK > 10%
Second line – sulfonylurea, pioglitazone, DPP-4 inhibitor, SGLT-2 inhibitor
Third line
- Triple therapy with metformin and two of the second-line drugs
- Insulin therapy
When triple therapy fails and patient’s BMI > 35kg/m2 – switching one of the drugs to a GLP-1 mimetic

26
Q

T2DM co-morbidities and complications

A

Infections
Diabetic retinopathy
Peripheral neuropathy
Autonomic neuropathy
CKD
Diabetic foot
Gastroparesis
Hyperosmolar hyperglycaemic state

27
Q

Hyperosmolar hyperglycaemic state

A

Rare but potentially fatal complication of type 2 diabetes
Characterised by hyperosmolality (water loss leads to very concentrated blood), high sugar levels (hyperglycaemia) and the absence of ketones
Presents with polyuria, polydipsia, weight loss, dehydration, tachycardia, hypotension and confusion
Medical emergency with high mortality, involve experienced seniors early
IV fluids and careful monitoring

28
Q

Metformin

A

Biguanide
Increases insulin sensitivity and decreases glucose production by the liver
It does NOT cause weight gain and does NOT cause hypoglycaemia
SE: GI (pain, nausea, diarrhoea), lactic acidosis
Patients with GI SE with standard-release metformin can try modified-release metformin

29
Q

SGLT-2 inhibitors

A

Empagliflozin, canagliflozin, dapagliflozin, ertugliflozin
SGLT-2 protein is found in proximal tubules of the kidneys -> acts to reabsorb glucose from the urine back into the blood – action is blocked so more glucose is excreted in the urine
Loss of glucose in the urine lowers the HbA1c, reduces the BP, leads to weight loss and improves HF
CAN cause hypoglycaemia
Empagliflozin and dapa – HF, dapa – CKD
SE: glycosuria, increased urine output and frequency, genital and UTI, weight loss, DKA, lower limb amputation, fournier’s gangrene

30
Q

Pioglitazone

A

Thiazolidinedione
Increases insulin sensitivity and decreases liver production of glucose
Does NOT cause hypoglycaemia
SE: weight gain, HF, increased risk of bone fractures, increased risk of bladder cancer

31
Q

Sulfonylureas

A

Gliclazide
Stimulate insulin release from the pancreas
SE: weight gain, hypoglycaemia

32
Q

Incretins

A

Hormones produced by the GI tract
Secreted in response to large meals and act to reduce blood sugar by:
- Increasing insulin secretion
- Inhibiting glucagon production
- Slowing absorption by the GI tract
Main incretin = GLP-1, inhibited by an enzyme called DPP-4

33
Q

DPP-4 inhibitors

A

Sitagliptin, alogliptin
Block the action of DPP-4, allowing increased incretin activity
Do NOT cause hypoglycaemia
SE: headaches, low risk of acute pancreatitis

34
Q

GLP-1 mimetics

A

Exenatide, liraglutide
Imitate the action of GLP-1
Given as subcut injections, liraglutide can be used for weight loss in non-diabetic obese patients
SE: reduced appetite, weight loss, GI symptoms